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Abstract 
Background: Vitamins are essential micronutrients with antioxidant potential that may provide a complementary 
treatment for patients with chronic diseases. Our aim was to assess the effect of vitamin supplementation on the 
antioxidant status and glycemic index of type 2 diabetes mellitus patients.
Methods: We performed a systematic review with meta‑analyses. Electronic searches were conducted in PubMed, 
Scopus, and Web of Science (December 2017). Randomized controlled trials evaluating the effect of any vitamin or 
vitamin complex supplementation on antioxidant status as primary outcome were included. The outcomes consid‑
ered were: reduction of malondialdehyde (MDA); augmentation of glutathione peroxidase (GPx); changes in total anti‑
oxidant capacity (TAC), enhance in superoxide dismutase enzyme—SOD, and thiobarbituric acid reactive substances 
(TBARS). Outcomes of glycemic control were also evaluated. Pairwise meta‑analyses were performed using software 
Review Manager 5.3.
Results: Thirty trials fulfilled the inclusion criteria, but only 12 could be included in the meta‑analyses of antioxidant 
outcomes. The most commonly studied vitamins were B, C, D and E. Vitamin E was related to significant reduction 
of blood glucose as well as glycated hemoglobin compared to placebo, while both vitamins C and E were mainly 
associated with reducing MDA and TBARS and elevating GPx, SOD and TAC, compared to placebo. However, outcome 
reports in this field are still inconsistent (e.g. because of a lack of standard measures).
Conclusions: Supplementation of vitamin E may be a valuable strategy for controlling diabetes complications and 
enhancing antioxidant capacity. The effects of other micronutrients should be further investigated in larger and well‑
designed trials to properly place these complementary therapies in clinical practice.
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Background
Diabetes mellitus (DM) is a chronic metabolic disorder 
characterized by an increase in blood glucose concentra-
tion (fasting blood glucose ≥ 126 mg/dL). There are cur-
rently 425 million people with diabetes worldwide, and 
this number is expected to reach 629 million by 2045, 
with type 2 diabetes (T2DM) being the most expressive 
form of the disease [1, 2]. The American Diabetes Asso-
ciation (ADA) and the European Association for the 
Study of Diabetes (EASD) consensus statement on the 
management of T2DM recommend life-style changes 
(healthy diet and physical activity) in combination with 
metformin at the time of diagnosis, and the addition 
of other medication in patients who do not achieve the 
desired glycemic control [1]. Lowering glycated hemo-
globin (HbA1c) to below 7% has been shown to be one 
of the primary endpoints in reducing microvascular com-
plications of DM and possibly macrovascular disease [3].
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Current evidence has demonstrated that oxidative 
stress plays an important role in the pathogenesis of 
chronic diseases such as DM [4, 5] and may diminish 
the antioxidative defense system of the body, increas-
ing the oxidative load [6]. Some studies have shown that 
individuals with low concentrations of antioxidants are 
at increased risk of diabetes complications [5, 7, 8] and 
that T2DM is associated with endothelial dysfunction [9]. 
These conditions may develop into macro and microvas-
cular diseases such as retinopathy, nephropathy, lower 
extremity amputations, coronary artery and cardiovascu-
lar diseases [10–12], which are the main causes of mor-
bidity and mortality worldwide [2].
The damaging effects of oxidative stress are mainly 
caused by the production of free radicals of oxygen and 
reactive oxygen species (ROS), but these substances can 
be modified by enzymatic or non-enzymatic antioxidants 
such as superoxide dismutase, vitamins, minerals, and 
polyphenols [13]. A previous study described how the 
supplementation with multivitamins in a population with 
a high prevalence of micronutrient deficiency signifi-
cantly decreased cerebrovascular disease mortality [14]. 
Other researchers have analyzed the antioxidant proper-
ties of natural products through chemical or biological 
methods. They have suggested that the consumption of 
food rich in antioxidants can retard or prevent the occur-
rence of disease [15, 16]. Nevertheless, previous system-
atic reviews and individual randomized controlled trials 
(RCTs) that have measured the effect of vitamin supple-
mentation on antioxidant status and glycemic control 
of diabetic patients have provided conflicting results, so 
that the benefit, or otherwise, of such supplementation 
remains uncertain [17–21].
Thus, we aimed to conduct a systematic review and 
pairwise meta-analyses to gather current evidence on the 
effects of any vitamin supplementation on antioxidant 
status in T2DM patients, in order to elucidate its real 
benefits.
Methods
We conducted and reported this systematic review and 
meta-analyses according to the Cochrane Recommen-
dations and PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines [22, 
23]. Two independent reviewers performed all the steps 
and discrepancies were solved by consensus with a third 
author.
Search strategies and inclusion criteria
We searched for relevant articles in the databases Pub-
Med, Scopus and Web of Science, without any time 
limit (updated December 18th, 2017). In addition, we 
conducted a manual search on the reference lists of the 
retrieved articles, reviews and trial registration databases 
to identify registers missed by the electronic search. 
Complete search strategies are presented in Additional 
file 1: Search strategies.
We included RCTs assessing adult patients (over 
18 years old) of any gender with any stage of T2DM and 
evaluating plasmatic antioxidant parameters or oxidative 
stress. Patients received vitamins (types A and/or B com-
plex and/or C and/or D and/or E or variants administered 
alone or in combination with other vitamins, micronutri-
ents or minerals) irrespective of form, dosage, duration 
or route of administration compared with placebo or no 
treatment or other vitamins (active control).
Two researchers independently screened titles and 
abstracts of the articles retrieved by the systematic 
review to identify irrelevant records. In a second stage, 
full text articles were evaluated to identify any of the fol-
lowing exclusion criteria: non-randomized controlled tri-
als (type of studies); interventions other than vitamins; 
individuals aged under 18 years; different populations or 
other type of diabetes (prediabetes, type 1 diabetes mel-
litus, gestational diabetes mellitus); outcomes measure 
other than antioxidant-related; trials published in non-
roman characters.
Data extraction and quality assessment
The following data were independently extracted from 
the included studies by two researchers: baseline char-
acteristics (authors’ names, year of publication, study 
design, country, sample size, gender, age, patients’ con-
dition, trial duration); methodological aspects; and 
clinical outcomes of interest. For primary outcomes, 
studies should report alterations in plasma antioxidant 
parameters or oxidative stress, such: vitamin levels, anti-
oxidant enzyme levels [superoxide dismutase (SOD), glu-
tathione peroxidase (GPx) and catalase (CAT)], oxidative 
stress biomarkers (e.g. harmful products MDA (malon-
dialdehyde) and thiobarbituric acid reactive substances 
(TBARS) or changes in plasma total antioxidant capac-
ity (TAC). Other changes in anthropometric and glyce-
mic parameters such as fasting blood glucose and HbA1c 
reduction, regarded as the ‘core outcome set’ for diabetes 
control, were also collected, when available.
Two different instruments, the Jadad score [24] and 
the Cochrane Collaboration’s tool for assessing the Risk 
of Bias [22], were used to evaluate the included studies’ 
methodological aspects, such as proper randomization, 
blinding, account for patients withdrawals and dropouts 
and other bias that may affect data interpretation.
Statistical analyses
Pairwise meta-analyses of the included RCTs were per-
formed for the main outcome measures whenever the 
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number of studies for each outcome of interest allowed. 
These analyses were conducted using the software Review 
Manager version 5.3 (The Nordic Cochrane Centre, The 
Cochrane Collaboration, Copenhagen, Denmark).
For each meta-analysis we used the random effects 
model and the inverse variance (IV) method to inter-
polate the mean differences (MD) or standardized (std.) 
mean differences (SMD) of each study from baseline. 
Results are reported with a 95% confidence interval (CI). 
A p value less than 0.05 (two-tailed) was considered 
indicative of a statistically significant difference between 
groups. The between-trial heterogeneity was assessed 
using the inconsistency index value  (I2)  (I2 > 50% indi-
cates high and significant heterogeneity) [22]. We also 
conducted sensitivity analyses to test the robustness of 
the results in order to evaluate the impact of any study 
on data heterogeneity. The analysis consisted of the hypo-
thetical sequential removal of studies from the meta-
analysis. When possible, subgroup analyses were also 
performed.
Results
The systematic search conducted in the three databases 
retrieved 1570 records and 196 were excluded as dupli-
cates. During the study’s title and abstract reading pro-
cess (screening), 1243 records were excluded and 104 
were considered for full-text appraisal, of which 25 arti-
cles were suitable for final analyses. Six articles were 
added from manual searches, finally yielding 31 articles 
representing 30 RCTs [25–55] (Fig. 1). The main charac-
teristics of the included studies are provided in Table 1.
All studies involved patients diagnosed with T2DM 
(n = 1430) and were conducted mainly in Iran (n = 9 tri-
als) [25, 32–34, 38, 41, 43, 44, 48, 51]; followed by the 
United Kingdom (n = 4) [42, 49, 52, 53] and the United 
States of America (n = 3) [28, 29, 47]. Evaluated treat-
ments comprised: vitamin B (n = 1 study) [25], vitamin 
C (n = 10) [26, 27, 29, 34, 37, 38, 40–42, 50]; vitamin D 
(n = 7) [30, 35, 43, 44, 48, 49, 53, 55]; vitamin E (n = 12) 
[28, 32–34, 36, 39, 45–47, 51, 52, 54], and a mixture of 
vitamins B, C and E (n = 1) [31]. In four of these trials 
(13.3%), vitamins were delivered by food fortification (oil 
or yogurt) [32, 44, 48, 51]. A placebo or negative control 
Fig. 1 Flowchart of the systematic review process
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Table 1 Characteristics of the included studies
Author, years Country Treatments N (sample) Duration 
(weeks)
Main 
outcome 
measures
Age (years) Male (%) Jadad score
Aghamoham‑
madi, 2011 
[25]
Iran Vitamin B9 5 mg/day
Placebo
70 8 MDA; TAC; 
vitamin con‑
centration
58.7 ± 7.2
55.6 ± 9.3
100 3
Anderson, 
2006 [26]
Wales Vitamin C 1000 mg/day
Placebo
20 6 TBARS 52.7 ± 6.9
53.6 ± 7.9
40.0 2
Antoniades, 
2004 [27]
Greece Vitamin C 2000 mg/day
Placebo
17 4 Vitamin con‑
centration; 
TNF
48.5 ± 6.6 
52.6 ± 5.9
58.8 1
Ble‑Castillo, 
2005 [28]
United States Vitamin E 800 IU/day
Placebo
33 6 Blood glucose; 
HbA1c; MDA; 
GPx
51.3 ± 14.0 
55.3 ± 11.6
0 2
Chen, 2006 
[29]
United States Vitamin C 800 mg/day
Placebo
32 4 Blood glucose; 
vitamin con‑
centration
50.0 ± 1.0 40.6 3
Dalan, 2016 
[30]
Singapore Vitamin D 4000 IU/day
Vitamin D 2000 IU/day
Placebo
64 16 HbA1c; 
vitamin 
concentra‑
tion; GSH
52.2 ± 8.2
54.8 ± 10.8
51.6 5
Gariballa, 2013 
[31]
Arab Emirates Vitamin complex (B, C, E)
Placebo
100 12 MDA; TNF; 
vitamin con‑
centration
52 (44–56)
51 (42–60)
41.0 2
Haghighat, 
2014 [32]
Iran Vitamin E enriched 
canola oil 15 ml/day 
Placebo oil
45 8 CRP; NO 55.9 ± 5.9 
55.2 ± 5.6
26.7 2
Hejazi, 2015 
[33]
Iran Vitamin E 400 IU/day
Placebo
27 6 Blood glucose; 
MDA
48.0 ± 6.3
46.6 ± 7.6
26.0 3
Jamalan, 2015 
[34]
Iran Vitamin C 1000 mg/day
Vitamin E 300 mg/day
80 4 Blood glucose; 
CRP; TNF
52.0 ± 8.0 100 2
Jorde, 2009 
[35]
Norway Vitamin D 40,000 IU/
week
Placebo
32 24 Blood glucose; 
HbA1c; 
vitamin con‑
centration
57.7 ± 9.7 
54.8 ± 5.9
56.2 2
Lai, 2008 [36] Japan Chromium 1000 µg
Vitamin E 800 IU + chro‑
mium
Placebo
30 24 Blood glucose; 
HbA1c; SOD; 
CAT; TBARS; 
TAS; GPx
53.2 ± 2.0
51.5 ± 1.7
50.5 ± 1.9
46.7 3
Lu, 2005 [37] Sweden Vitamin C 3000 mg/day
Placebo
20 2 Blood glucose; 
HbA1c; IL‑6
– 60.0 2
Mahmoudab‑
adi, 2014 [38]
Iran Eicosapentaenoic acid 
500 mg/day
Vitamin C 200 mg/day
Vitamin C + eicosapen‑
taenoic acid
Placebo
81 8 Blood glucose; 
HbA1c; 
vitamin con‑
centration; 
SOD; MDA; 
TAC; GPx
54.0 ± 5.0 
53.0 ± 5.0 
52.0 ± 6.0 
50.0 ± 8.0
100 2
Manzella, 2001 
[39]
Italy Vitamin E 600 mg/day
Placebo
50 16 HbA1c; TBARS 64.3 ± 4.7 
65.1 ± 3.9
– 3
Mason, 2016 
[40]
Australia Vitamin C 1,000 mg/day
Placebo
13 16 Insulin; GSH; 
IL‑6
59.4 ± 3.5 92.3 3
Mazloom, 2011 
[41]
Iran Vitamin C 1,000 mg/day
Placebo
27 6 Plasma lipid 
parameters; 
MDA
47.0 ± 8.9 
46.6 ± 7.6
42.1 2
Mullan, 2002 
[42]
United King‑
dom
Vitamin C 500 mg/day
Placebo
30 4 Plasma lipid 
parameters; 
LDL‑ox
61.0 ± 6.5
57.9 ± 6.6
73.4 3
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was the main comparator in 29 studies (96.7%), while 
eight trials (26.7%) included head-to-head comparisons. 
Duration of treatment ranged from two to 24 weeks and 
patients’ age ranged from 46 to 72 years.
Overall, the methodological quality of included tri-
als was low to moderate, with a mean Jadad Score of 2.7 
(range 1–5). All studies scored on randomization, but 
only 20% of them properly described how randomiza-
tion was achieved. Almost all trials (90%) accounted for 
Table 1 continued
Author, years Country Treatments N (sample) Duration 
(weeks)
Main 
outcome 
measures
Age (years) Male (%) Jadad score
Nikooyeh, 
2011/2014 
[43, 44]
Iran Yogurt (150 mg cal‑
cium/250 mL)
Vitamin D fortified 
(150 mg cal‑
cium + 500 IU/250 mL)
Vitamin D fortified 
(250 mg of cal‑
cium + 500 IU/250 mL)
*Two bottles/
day = 500 mL/day
90 12 Blood glucose; 
HbA1c; 
vitamin con‑
centration; 
SOD; MDA
50.8 ± 6.6 
51.4 ± 5.4
49.9 ± 6.2
38.9 2
Paolisso, 2000 
[45]
Italy Vitamin E 600 mg/day
Placebo
40 8 TBARS; vitamin 
concentra‑
tion
58.3 ± 6.4 
56.7 ± 5.3
52.5 3
Park, 2002 [46] Korea Vitamin E 200 mg/day
Placebo
98 8 Blood glucose; 
HbA1c; SOD; 
CAT
49.4 ± 9.3 
49.5 ± 10.1
59.2 2
Reaven, 1995 
[47]
United States Vitamin E 1600 lU/day
Placebo
21 10 Blood glucose; 
HbA1c; 
LDL‑ox
60.8 ± 6.1
61.8 ± 8.4
100 2
Shab‑Bidar, 
2015 [48]
Iran Vitamin D fortified Yogurt 
500 UI, 500 ml/day 
Yogurt
100 12 Blood glucose; 
HbA1c; SOD; 
MDA; TAC; 
GSH
52.6 ± 6.3 
52.4 ± 8.4
43.0 3
Sugden 2007 
[49]
United King‑
dom
Vitamin D 100,000 UI/day 
Placebo
34 8 HbA1c; 
vitamin 
concentra‑
tion; NO
64.9 ± 10.3 
63.5 ± 9.5
52.9 5
Tessier, 2009 
[50]
Canada Vitamin C 500 mg/day
Vitamin C 1000 mg/day
Placebo
36 12 Plasma lipid 
parameters; 
GSH
72.0 ± 5.0
72.0 ± 4.0
71.0 ± 4.0
22.2 3
Vafa, 2015 [51] Iran Vitamin E enriched 
canola oil 15 ml/day 
Canola oil
45 8 Blood glucose; 
MDA; TAC
55.9 ± 5.9
55.2 ± 5.6
73.3 4
Winterbone, 
2007 [52]
United King‑
dom
Vitamin E 1200 IU 
α‑tocopherol/day 
Placebo
19 4 Blood glucose; 
insulin; 
vitamin con‑
centration
62.7 ± 1.8
61.9 ± 1.9
100 2
Witham, 2010 
[53]
United King‑
dom
Vitamin D3 100,000 IU/
day
Vitamin D3 200,000 IU/
day
Placebo
41 16 HbA1c; 
vitamin 
concentra‑
tion; GSH
65.3 ± 11.1
63.3 ± 9.6
66.7 ± 9.7
67.2 3
Wu, 2007 [54] Australia Vitamin E α‑tocopherol 
500 mg/day
Vitamin E mixed toco‑
pherols 500 mg/day
Placebo
55 6 SOD; GPx 64.0 ± 7.0
58.0 ± 4.0
62.0 ± 7.0
74.5 2
Yiu, 2013 [55] China Vitamin D 500 IU/day
Placebo
100 12 Blood glucose; 
HbA1c; SOD
65.8 ± 7.3
64.9 ± 8.9
50.0 4
CAT catalase; CRP C-reactive protein; GPx glutathione peroxidase; GSH glutathione; HbA1c glycated hemoglobin; IL-6 interleukin; LDL-ox oxidized low-density 
lipoprotein; MDA malondialdehyde; NO nitric oxide; SOD superoxide dismutase; TAC total antioxidant capacity; TBARS thiobarbituric acid reactive substances; TNF 
tumor necrosis factor
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patient’ withdrawals or dropouts, and half of the studies 
was double-blinded. However, only two trials described 
the blinding methods. The Risk of Bias assessment (see 
Additional file  1: Quality assessment), established that 
trials were of low risk of bias (> 75%) in the domains of 
randomization, incomplete outcome data and selec-
tive reporting. Allocation concealment was considered 
unclear in 25 trials (86.2%), and studies often failed to 
provide details regarding blinding of participants or out-
come measures. Overall, 70% of trials were funded by 
industries or reported conflict of interest.
Considering the primary outcomes of interest related 
to antioxidant status, 12 RCTs (encompassing 13 arti-
cles) were able to be included in the meta- analyses (all 
of them compared vitamin to placebo) [25, 28, 33, 36, 38, 
39, 41, 43–45, 48, 51, 54]. Not all studies were statisti-
cally evaluated since outcomes were not comparable (e.g. 
because of lack of raw data). Gathering evidence, espe-
cially on antioxidant potential, was hampered by the lack 
of standardization of outcome reporting in the clinical 
trials (e.g. inconsistent reporting, using different meas-
ures, scales and units).
Meta-analyses were obtained for augmentation of GPx 
levels (Units/gram of Hemoglobin—U/g Hb), reduction 
in plasma MDA (nmol/L) and TBARS (µmol/L) reduc-
tions, and favorable changes in TAC (mmol/L) and SOD 
(U/g Hb). In these cases, no subgroup analyses were 
performed due to the limited number of studies. Over-
all, results were statistically different from placebo to 
favored the use of vitamins with values of MD 9.40 (95% 
CI [7.79; 11.00]) for GPx (p < 0.001) and MD − 0.53 (95% 
CI [− 0.81; − 0.25]) for MDA (p < 0.001), with  I2 values of 
44 and 47%, respectively. Vitamins were also superior to 
placebo in reducing TBARS with an overall effect size of 
SMD − 4.84 (95% CI [− 6.01; − 3.67]) (p < 0.001;  I2 = 54%) 
and in increasing TAC (SMD 0.38 [0.11; 0.65]; p = 0.006) 
and SOD levels (SMD 0.64 [0.11; 1.17]; p = 0.02). These 
positive results came mostly from studies where the 
interventions were vitamin E (n = 7 trials) [28, 33, 36, 
39, 45, 51, 54]; vitamin C (n = 2) [38, 41] and vitamin D 
(n = 2) [44, 48] (see Fig. 2).
The meta-analyses of the glycemic control parameters 
(17 included trials obtained from 18 articles) are shown 
in Figs. 3, 4 [28–30, 33, 35–39, 43, 44, 46–49, 52, 53, 55]. 
No statistical differences were observed in subgroup 
analyses comparing vitamins C or D with placebo. How-
ever, for both outcomes of mean change in blood glucose 
(mg/dL) and reduction of HbA1c (as a percentage), the 
effects of vitamin E were significantly better than the 
control (values of MD − 13.89 (95% CI [− 19.89; − 7.89]) 
and MD − 0.47 (95% CI [− 0.69; − 0.26]), respectively).
The moderate to high heterogeneity of some meta-
analyses  (I2 ranging from 15 to 71%) was caused by more 
than one study and can be considered acceptable in this 
context. Sensitivity analyses were conducted with all the 
meta-analyses (data not shown) and despite the sequen-
tial hypothetical removal of studies with reduction in the 
heterogeneity, the results remained unchanged.
Discussion
Our study is the first systematic review with meta-anal-
ysis to evaluate the available evidence of vitamin sup-
plementation in T2DM patients for the improvement of 
antioxidant status in different ways (GPx, SOD and TAC 
levels augmentation and reduction in MDA and TBARS 
products). Previous studies have focused on glycemic 
control, insulin resistance and changes in endothelial 
functions [18, 20, 21, 56].
Our results revealed that supplementation of certain 
vitamins in T2DM, especially vitamin E, can produce a 
significant impact on the parameters of antioxidant sta-
tus and glycemic control, which may positively benefit 
patients. Vitamin C was more related to changes in anti-
oxidant status, while little evidence was found for the 
effect of other vitamins (e.g. D or B).
The beneficial effects of vitamin E may be explained 
by the reduction of the damaging effects of free radicals 
on the structural and functional components of cells and 
vessel walls [56, 57]. It is believed that diabetes is associ-
ated with increased oxidative stress because of increased 
blood concentrations of thiobarbituric acid reactive sub-
stances and serum malondialdehyde, the end products of 
lipid peroxidation [58]. The adverse physiological effects 
which result include increased leakiness of cell mem-
branes where the structural integrity of membranes has 
been altered; inactivation of membrane bound enzymes 
and surface receptors and the involvement of oxidized 
LDL (LDL-ox). When total antioxidant status (TAC) is 
high enough to combat the oxidative stress, the MDA 
and TBARS levels are in the normal limits and vice versa. 
Antioxidants decrease the oxidative damage directly by 
reacting with free radicals or indirectly by inhibiting the 
activity or expression of free radicals [59, 60].
Non-enzymatic antioxidants such as vitamins C and 
E and glutathione interrupt free radical chain reactions. 
The combination of these vitamins appears to be prom-
ising. Although only one RCT evaluating a mixed vita-
min complex was found in our systematic review [31], a 
previous study reported that antioxidant combinations 
might be an appropriate formula for the management of 
diabetes [61]. A 3-month study on the supplementation 
of vitamins C and E showed that patients’ blood glucose 
decreased while SOD and glutathione levels increased 
[62]. Moreover, the long-term use of dietary supple-
ments, including multivitamin or mineral complexes 
showed benefits in C-reactive protein, HDL cholesterol, 
Page 7 of 12Balbi et al. Diabetol Metab Syndr  (2018) 10:18 
Fig. 2 Forest plots for the outcomes of antioxidant status. a Augmentation of GPx level (U/g Hb). b Reduction of MDA (nmol/L). c Reduction of 
TBARS (µmol/L). d Changes in TAC (mmol/L). e Changes in SOD (U/g). Statistical method: Mean difference (MD) and Std. Mean Difference (SMD), IV, 
Random, 95% confidence interval
Page 8 of 12Balbi et al. Diabetol Metab Syndr  (2018) 10:18 
triacylglycerides, serum homocysteine, blood pressure 
and incidence of diabetes [14, 63–65]. However, vitamin 
C alone did not present a greater profile than vitamin E.
In the literature, vitamin D is related to gene expres-
sion control which may trigger a biological response to 
oxidative stress, such as inhibiting nitric oxide synthase 
(iNOS) or increasing glutatione levels [66]. The antioxi-
dant effect of vitamin D is among the most recent non-
calcemic roles suggested for this compound [67]. There is 
evidence from both humans and animal models suggest-
ing that vitamin D may play an important role in modify-
ing the risk of diabetes [66, 68]. Low vitamin D status is 
associated with future macrovascular events in patients 
with T2DM. This association may be the result of the 
link between vitamin D status and the renin-angiotensin 
system, endothelial function, blood pressure, or even 
chronic inflammation [20, 69, 70]. However, our results 
were constrained in defining a vitamin D antioxidant 
profile, since few RCTs involving this micronutrient were 
included [43, 44].
Some trials [32, 44, 48, 51] did not use direct drug 
supplementation but incorporated the vitamin in food 
(e.g. oil, yogurt), which may have affected final results. 
Moreover, because the total daily dosage of vitamin 
intake and treatment duration varied among the stud-
ies, effects on antioxidant and glycemic profiles may have 
been underestimated. Regimens for vitamin C varied 
from 500 to 3000 mg/day; for vitamin E they ranged from 
400 to 1600 IU/day and for vitamin D doses were of 500 
to 200,000  IU/day. Longer period trials with reasonable 
lower daily doses may increase the intracellular concen-
tration of vitamins and result in an adequate effect that 
should then be evaluated.
In spite of the encouraging results reported above, the 
small number of studies properly reporting data pre-
vented a fully satisfactory assessment of the outcomes 
related to antioxidant status. Moreover, methodological 
aspects of the included trials demonstrated low to mod-
erate quality, especially concerning accurate description 
of randomization and blinding. The moderate to high 
heterogeneity in some meta-analyses can be explained 
by the differences in the intrinsic characteristics of stud-
ies, the conduct and design of trials with low quality, the 
small sample sizes of some studies, patient’s conditions 
with possible comorbidities, different pharmacological 
treatments, and differences in outcome measures.
Fig. 3 Forest plot for the outcome measure of blood glucose mean change from baseline (mg/dL). Statistical method: Mean difference (MD), IV, 
Random, 95% confidence interval
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The marked heterogeneity in the outcomes reporting 
of oxidative stress and antioxidant capacity might be due 
the lack of standardization in the selection or measure-
ment of the outcome in clinical trials. Different measures 
and units are usually employed (e.g., enzyme levels (cata-
lase, superoxide dismutase); FRAP—ferric reducing abil-
ity of plasma assay; ORAC—oxygen radical absorbance 
capacity assay; TAS—total antioxidant status, among 
others) [71, 72]. This can be justified in part because of 
the range of substances and antioxidant components in 
the organism, together with the difficulty in measuring 
them all at once. The issue of lack of outcome standardi-
zation is common to different areas, but has been associ-
ated with a bad reporting practice—outcome switching, 
and hamper comparisons between interventions [73]. 
The development of a core outcome set for antioxidant 
status in chronic diseases is important for study design 
and could minimize bias. Measures such as TAC, TBARS 
and MDA could be employed as standard.
Our study has some limitations. We included RCTs 
with differences in methodological design and popula-
tion characteristics (e.g. age, gender, disease stage and 
comorbidities, diabetes treatments, study duration) and 
none of them were sufficiently powerful due to the rela-
tively small number of participants. There was some dif-
ficulty in finding and gathering trials of the same vitamin 
or vitamin complex assessing similar outcomes. We were 
able to statistically analyze three vitamins (C, D and E), 
but other micronutrients and vitamin combinations 
(especially vitamins C and E) should be better investi-
gated. Subgroup meta-analyses were poorly obtained.
We strongly recommend that further well-designed, 
large-scale, long-term head-to-head controlled trials and 
meta-analyses be carried out to demonstrate the effects 
of individual or multivitamin supplementations on 
T2DM, since previous results are promising.
Conclusions
The consumption of vitamin E (alone or in combination) 
promotes health benefits since it affects plasma anti-
oxidant capacity and the concentration of enzymes and 
reduces MDA and TBARS levels. T2DM patients have a 
high risk of experiencing micro and macrovascular com-
plications, and daily vitamin supplementation provides 
Fig. 4 Forest plot for the outcome measure of HbA1c mean change from baseline (%). Statistical method: Mean difference (MD), IV, Random, 95% 
confidence interval
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an alternative strategy for metabolic control, in addi-
tion to the combination of diet, exercise and medication. 
These substances may represent a step forward in dis-
ease management. Further studies should be conducted 
to strengthen this evidence, especially for defining doses 
and regimen of vitamin E, and support its use in daily 
practice.
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